menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Pfizer`s chief scientist Mikael Dolsten to step down

    REUTERS

    HHS asks Supreme Court to reject Pfizer`s anti-kickback appeal

    FIERCEPHARMA

    Pfizer gains powerful allies in its Vyndaqel copay case

    FIERCEPHARMA

    Pfizer petitions Supreme Court over anti-kickback case

    ENDPTS

    Pfizer’s VYNDAQEL/VYNDAMAX Reduced the Risk of All-Cause Mortality

    BIOSPACE

    Pfizer’s VYNDAQEL/VYNDAMAX Reduces Risk of All-Cause Mortality by 41% in ATTR-CM

    BUSINESSWIRE

    Pfizer fails in another challenge to U.S. anti-kickback policies

    FIERCEPHARMA

    Dutch HTA Calls for Big Discount For Pfizer’s Vyndaqel

    PINK SHEET

    Pfizer`s new Vyndaqel, Vyndamax reach blockbuster threshold

    FIERCE PHARMA

    Pfizer`s Vyndaqel zooms toward blockbusterland, even amid COVID

    FIERCE PHARMA

    Pfizer targets anti-kickback rules in Vyndaqel Medicare suit

    FIERCE PHARMA

    Alnylam scores speedy FDA approval for rare liver disease

    FIERCE PHARMA

    Pfizer`s Vyndaqel franchise, buoyed by diagnose, is poised for `a decisive beat`

    FIERCE PHARMA

    After leadership shuffle, Akcea hands heart drug to Pfizer for $250M

    FIERCE BIOTECH

    Alnylam`s Onpattro back in the game against Ionis, thanks to NICE U-turn

    FIERCE PHARMA

    Approved new drug for rare disease

    ANVISA

    Pfizer’s Vyndaqel slows neurodegenerative disease, analysis shows

    PHARMATIMES

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.